PHAS - PhaseBio Pharmaceuticals appoints Jonathan Birchall as Chief Commercial Officer

PhaseBio Pharmaceuticals (NASDAQ:PHAS) has appointed Jonathan Birchall as Chief Commercial Officer. Prior to this appointment, Birchall was Vice President and U.S. Head of Genentech's thrombolytics franchise. In the new role, Birchall lead PhaseBio's efforts to build a critical-care focused commercial organization to support the U.S. launch of its lead product candidate, bentracimab. Recently, PhaseBio reported pivotal data for bentracimab. The firm plans to submit its Biologics License Agreement with the FDA in mid-2022, which, if approved, could position U.S. launch of bentracimab in early 2023.

For further details see:

PhaseBio Pharmaceuticals appoints Jonathan Birchall as Chief Commercial Officer